Literature DB >> 3114373

Identification and sequence of the VH gene elements encoding a human anti-DNA antibody.

S Hoch, J Schwaber.   

Abstract

Antibodies to DNA similar to those found in patients with systemic lupus erythematosus (SLE) and autoimmune mice can be derived from the lymphocytes of normal individuals. It is not known whether these normal derived anti-DNA antibodies are made from the same VH gene elements as the anti-DNA antibodies made by SLE patients. To begin to answer this question, we examined mu chain cDNA clones from human hybrid clone C6B2 producing anti-DNA antibodies. The sequence of the 500 base pair restriction fragment containing the variable region (5' terminus) was determined and was sequenced. This antibody uses a VHII heavy chain subgroup gene, a J3 joining segment, a hitherto unknown D segment, and a previously reported leader sequence. Significant homology was found to a mouse anti-DNA antibody sequence in the use of VH subgroup in J3, and in the hypervariable regions with a shared Ser-Tyr construction in CDR1 and an identical five amino acid residue stretch in CDR2. Comparison with the limited sequence data of published SLE monoclonal anti-DNA antibodies, both human and mouse, suggests that this shared Ser-Tyr may be important in some but not all antibodies to DNA. Comparison of C6B2 antibody is made with other known antibody sequences with identification of those residues likely to be part of the antigen binding site.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114373

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Sequence analyses of three immunoglobulin G anti-virus antibodies reveal their utilization of autoantibody-related immunoglobulin Vh genes, but not V lambda genes.

Authors:  D F Huang; T Olee; Y Masuho; Y Matsumoto; D A Carson; P P Chen
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

2.  Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody.

Authors:  W A Marasco; J Bagley; C Zani; M Posner; L Cavacini; W A Haseltine; J Sodroski
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

Review 3.  Autoantibodies and antibacterial antibodies: from both sides now.

Authors:  R A Watts; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

4.  Evidence for failure of V(D)J recombination in bone marrow pre-B cells from X-linked agammaglobulinemia.

Authors:  J Schwaber
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 5.  New roles for rheumatoid factor.

Authors:  D A Carson; P P Chen; T J Kipps
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

6.  Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype.

Authors:  A Manheimer-Lory; J B Katz; M Pillinger; C Ghossein; A Smith; B Diamond
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

7.  Premature termination of variable gene rearrangement in B lymphocytes from X-linked agammaglobulinemia.

Authors:  J Schwaber; R H Chen
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

8.  Immunoglobulin gene sequence analysis to further assess B-cell origin of multiple myeloma.

Authors:  D D Biggs; P Kraj; J Goldman; L Jefferies; C Carchidi; K Anderson; L E Silberstein
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

9.  Characterization of a human monoclonal autoantibody directed to cardiolipin/beta 2 glycoprotein I produced by chronic lymphocytic leukaemia B cells.

Authors:  X Mariette; Y Levy; M L Dubreuil; L Intrator; F Danon; J C Brouet
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

10.  Structure of the VH and VL segments of monoreactive and polyreactive IgA autoantibodies to DNA in patients with systemic lupus erythematosus.

Authors:  M T Kasaian; H Ikematsu; J E Balow; P Casali
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.